2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 343-345
Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Young Adult
PAPER

430 Integrated multi-omic and functional profiling identifies a 1q21.3–MLLT11 program associated with resistance to CD19 CAR T-cell therapy in large B-cell lymphoma

Hesong Zou, Chen Qiu2, ZhuoXin Zhang Jr3, Wei LIU4, Huimin Liu5, Yi Wang6, Ting Xie7, Chenxing Du, MD8, Rui Lv, MD9, Shuhua Yi, DO10, Yan Xu, MD11, Gang An, MD12, Lu-Gui Qiu, PhD13, Zhen Yu, MD14, Dehui Zou, MD15
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background

Primary resistance and early progression remain major barriers to durable benefit from CD19-directed chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL). Although antigen loss contributes to treatment failure, the pretreatment genomic, malignant-cell, and tumor-microenvironmental states associated with resistance remain incompletely defined. We integrated multi-omic profiling with functional perturbation to identify clinically relevant tumor programs associated with CAR T-cell failure.

Methods

Pretreatment tumors from a prospective institutional cohort of 44 patients with LBCL treated with CD19 CAR T cells were profiled by whole-exome sequencing (WES; 34 patients and 48 longitudinally collected specimens), bulk RNA sequencing (RNA-seq; 23 patients), and single-cell RNA-seq (12 patients). Patients were classified as primary nonresponders (NR), early progressors (progression-free survival [PFS] <90 days), late progressors, or durable responders. Somatic mutations and copy-number alterations (CNAs), transcriptional programs, malignant B-cell clonotypes, and immune-cell states were analyzed across platforms. An external CAR T-cell–treated cohort (n=43) was used for validation. MLLT11 was knocked down in MLLT11-high Karpas-422 cells and overexpressed in MLLT11-low U2932 cells, followed by co-culture with CD19 CAR T cells across multiple effector-to-target ratios and time points.

Results 

NR tumors displayed greater chromosomal instability. Pretreatment 1q21.3 amplification was enriched in primary NR compared with durable responders (6/9 [66.7%] vs 2/14 [14.3%]; Fisher exact P=0.0228) and was associated with inferior overall survival. Copy number at the MLLT11 locus correlated with bulk MLLT11 expression (r=0.77; n=18), identifying MLLT11 as a dosage-linked candidate within the amplicon. High MLLT11 expression was associated with shorter PFS in both the institutional bulk cohort (log-rank P=0.0003) and an external dataset (P=0.013).

Single-cell analysis localized MLLT11 predominantly to dominant-clone malignant B cells and identified an MLLT11-high state enriched for cell-cycle and chromatin-remodeling programs, with reduced antigen-presentation and interferon-related signaling. This malignant-cell state co-occurred with an immune-depleted microenvironment characterized by fewer activated/memory CD8 T cells and plasmacytoid dendritic cells, enrichment of terminal-effector CD8 states, and myeloid remodeling. Bulk RNA-seq deconvolution supported these cellular shifts.

Functionally, MLLT11 knockdown in Karpas-422 cells increased susceptibility to CAR T-cell killing, whereas MLLT11 overexpression in U2932 cells increased tumor-cell survival following CAR T-cell exposure across multiple experimental conditions. Knockdown was accompanied by increased surface CD19 and HLA-ABC expression, while overexpression produced context-dependent changes in immune-recognition markers, including reduced HLA-DR.

Conclusions

Integrated genomic, bulk, and single-cell profiling identifies a 1q21.3–MLLT11 program associated with primary resistance and adverse outcomes after CD19 CAR T-cell therapy in LBCL. MLLT11-high dominant malignant B-cell states co-occur with impaired immune-recognition programs and an immune-depleted microenvironment, while bidirectional perturbation functionally links MLLT11 expression to CAR T-cell sensitivity. These findings nominate 1q21.3/MLLT11 as a candidate pretreatment biomarker and functional contributor to CAR T-cell resistance, warranting prospective validation and further mechanistic investigation.

Hesong Zou: No relevant conflicts of interest to declare.